Literature DB >> 24200675

New clinical and experimental insights into Old World and neotropical ocular toxoplasmosis.

Alexander W Pfaff1, Alejandra de-la-Torre2, Elise Rochet3, Julie Brunet3, Marcela Sabou3, Arnaud Sauer4, Tristan Bourcier4, Jorge E Gomez-Marin5, Ermanno Candolfi6.   

Abstract

Retinal lesions or other ocular manifestations are serious consequences of infection with the protozoan parasite Toxoplasma gondii. Whilst classically considered a consequence of congenital transmission, recent screening studies estimated that 2% of T. gondii seropositive persons in Europe and North America have retinal lesions, most of them persisting unnoticed. The situation is more dramatic in South America, probably due to the predominance of virulent strains. Some of these strains seem to exhibit ocular or neuronal tropism and are responsible for severe ocular lesions. Despite the medical importance, the physiopathological mechanisms have only recently begun to be elucidated. The particular immune-privileged situation in the eye has to be considered. Studies on French patients showed low or undetectable ocular parasite loads, but a clear Th1/Th17 type immune reaction. Suitable mouse models have appeared in the last few years. Using such a model, IL-17A proved to impair parasite control and induce pathology. In contrast, in South American patients, the parasite seems to be much less efficiently controlled through a Th2 type or suppressive immune response that favors parasite replication. Finally, several host genetic markers controlling immune response factors have been associated with ocular involvement of T. gondii infection, mainly in South America.
Copyright © 2013 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Human studies; Inflammation; Mouse models; Ocular toxoplasmosis; Parasite strains; South America; Toxoplasma gondii

Mesh:

Year:  2013        PMID: 24200675     DOI: 10.1016/j.ijpara.2013.09.007

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  25 in total

Review 1.  Toxoplasma Effectors Targeting Host Signaling and Transcription.

Authors:  Mohamed-Ali Hakimi; Philipp Olias; L David Sibley
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

2.  Help in the Choice of Automated or Semiautomated Immunoassays for Serological Diagnosis of Toxoplasmosis: Evaluation of Nine Immunoassays by the French National Reference Center for Toxoplasmosis.

Authors:  O Villard; B Cimon; C L'Ollivier; H Fricker-Hidalgo; N Godineau; S Houze; L Paris; H Pelloux; I Villena; E Candolfi
Journal:  J Clin Microbiol       Date:  2016-10-12       Impact factor: 5.948

3.  Genetic Polymorphisms in Cytokine Genes in Colombian Patients with Ocular Toxoplasmosis.

Authors:  C A Naranjo-Galvis; A de-la-Torre; L E Mantilla-Muriel; L Beltrán-Angarita; X Elcoroaristizabal-Martín; R McLeod; N Alliey-Rodriguez; I J Begeman; C López de Mesa; J E Gómez-Marín; J C Sepúlveda-Arias
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

4.  Interleukin-6-driven inflammatory response induces retinal pathology in a model of ocular toxoplasmosis reactivation.

Authors:  Élise Rochet; Julie Brunet; Marcela Sabou; Luc Marcellin; Tristan Bourcier; Ermanno Candolfi; Alexander W Pfaff
Journal:  Infect Immun       Date:  2015-03-09       Impact factor: 3.441

5.  Ocular cytokinome is linked to clinical characteristics in ocular toxoplasmosis.

Authors:  Alejandra de-la-Torre; Alexander W Pfaff; Michael E Grigg; Odile Villard; Ermanno Candolfi; Jorge E Gomez-Marin
Journal:  Cytokine       Date:  2014-04-16       Impact factor: 3.861

6.  Intraocular levels of interleukin 17A (IL-17A) and IL-10 as respective determinant markers of toxoplasmosis and viral uveitis.

Authors:  Arnaud Sauer; Odile Villard; Catherine Creuzot-Garcher; Christophe Chiquet; Jean-Paul Berrod; Claude Speeg-Schatz; Tristan Bourcier; Ermanno Candolfi
Journal:  Clin Vaccine Immunol       Date:  2014-11-05

7.  Direct genetic characterization of Toxoplasma gondii from clinical samples from Denmark: not only genotypes II and III.

Authors:  P Jokelainen; J-B Murat; H V Nielsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-03       Impact factor: 3.267

8.  Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro.

Authors:  Joshua B Radke; Jeremy N Burrows; Daniel E Goldberg; L David Sibley
Journal:  ACS Infect Dis       Date:  2018-07-25       Impact factor: 5.084

Review 9.  Toxoplasmosis and epilepsy--systematic review and meta analysis.

Authors:  Edgard B Ngoungou; Devender Bhalla; Amandine Nzoghe; Marie-Laure Dardé; Pierre-Marie Preux
Journal:  PLoS Negl Trop Dis       Date:  2015-02-19

Review 10.  Protozoan persister-like cells and drug treatment failure.

Authors:  Michael P Barrett; Dennis E Kyle; L David Sibley; Joshua B Radke; Rick L Tarleton
Journal:  Nat Rev Microbiol       Date:  2019-08-23       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.